Table 6.
Descriptive analysis of patients with solicited adverse events, all patients (N = 761)
| |
All Patients N = 761 |
OM N = 186 |
LM N = 152 |
AM N = 216 |
OLC N = 47 |
OAC N = 68 |
OC N =48 |
OMS N = 44 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solicited side effects | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % |
| Any |
662 |
87.0 |
157 |
84.4 |
135 |
88.8 |
185 |
85.7 |
45 |
95.7 |
61 |
89.7 |
44 |
91.7 |
35 |
79.6 |
| Weight increase |
530 |
69.7 |
144 |
77.4 |
99 |
65.1 |
140 |
64.8 |
42 |
89.4 |
49 |
72.1 |
30 |
62.5 |
26 |
59.1 |
| Sedation |
369 |
48.5 |
100 |
53.8 |
56 |
36.8 |
101 |
46.8 |
27 |
57.5 |
37 |
54.4 |
23 |
47.9 |
25 |
56.8 |
| Cognitive dysfunctions |
321 |
42.2 |
74 |
39.8 |
68 |
44.7 |
78 |
36.1 |
25 |
53.2 |
36 |
52.9 |
26 |
54.2 |
14 |
31.8 |
| Sexual dysfunctions |
294 |
38.6 |
78 |
41.9 |
48 |
31.6 |
79 |
36.6 |
30 |
63.8 |
33 |
48.5 |
15 |
31.3 |
11 |
25.0 |
| Gastroint. disorders |
221 |
29.0 |
40 |
21.5 |
58 |
38.2 |
59 |
27.3 |
16 |
34.0 |
15 |
22.1 |
19 |
39.6 |
14 |
31.8 |
| Dizziness |
215 |
28.3 |
46 |
24.7 |
44 |
29.0 |
64 |
29.6 |
13 |
27.7 |
19 |
27.9 |
15 |
31.3 |
14 |
31.8 |
| Tremor |
195 |
25.6 |
25 |
13.4 |
62 |
40.8 |
35 |
16.2 |
22 |
46.8 |
23 |
33.8 |
22 |
45.8 |
6 |
13.6 |
| Thirst |
169 |
22.2 |
30 |
16.1 |
58 |
38.2 |
36 |
16.7 |
18 |
38.3 |
12 |
17.7 |
10 |
20.8 |
5 |
11.4 |
| Insomnia |
165 |
21.7 |
41 |
22.0 |
33 |
21.7 |
46 |
21.3 |
12 |
25.5 |
12 |
17.7 |
14 |
29.2 |
7 |
15.9 |
| Polyuria/nycturia |
109 |
14.3 |
21 |
11.3 |
49 |
32.2 |
16 |
7.4 |
12 |
25.5 |
5 |
7.4 |
4 |
8.3 |
2 |
4.6 |
| Menstrual disorders |
65 |
8.5 |
16 |
8.6 |
11 |
7.2 |
23 |
10.7 |
2 |
4.3 |
6 |
8.8 |
4 |
8.3 |
3 |
6.8 |
| Thyroid disorders |
58 |
7.6 |
5 |
2.7 |
31 |
20.4 |
7 |
3.2 |
7 |
14.9 |
2 |
2.9 |
6 |
12.5 |
0 |
0.0 |
| Akathisia |
54 |
7.1 |
12 |
6.5 |
7 |
4.6 |
18 |
8.3 |
1 |
2.1 |
9 |
13.2 |
3 |
6.3 |
4 |
9.1 |
| Parkinson syndrome |
21 |
2.8 |
3 |
1.6 |
5 |
3.3 |
6 |
2.8 |
1 |
2.1 |
3 |
4.4 |
2 |
4.2 |
1 |
2.3 |
| Hyperprolactinaemia |
18 |
2.4 |
3 |
1.6 |
5 |
3.3 |
3 |
1.4 |
3 |
6.4 |
3 |
4.4 |
0 |
0.0 |
1 |
2.3 |
| Tardive dyskinesia |
16 |
2.1 |
1 |
0.5 |
4 |
2.6 |
7 |
3.2 |
1 |
2.1 |
1 |
1.5 |
2 |
4.2 |
0 |
0.0 |
| Dystonia |
16 |
2.1 |
2 |
1.1 |
2 |
1.3 |
5 |
2.3 |
1 |
2.1 |
0 |
0.0 |
3 |
6.3 |
3 |
6.8 |
| QTc-Prolongation | 8 | 1.1 | 0 | 0.0 | 3 | 2.0 | 3 | 1.4 | 0 | 0.0 | 1 | 1.5 | 1 | 2.1 | 0 | 0.0 |
Abbreviations: N number of patients, OM Olanzapine monotherapy, LM Lithium monotherapy, AM Anticonvulsive monotherapy, OLC Olanzapine/lithium combination therapy, OAC Olanzapine/anticonvulsive combination therapy, OC Other combinations of mood-stabilizers, OMS Other mood stabilizing therapy.